Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar. Marketed as “Product,” it is a biosimilar to Neulasta®. Developed and manufactured by Biocon Biologics, the product will be promoted, sold, and distributed in Japan by Sandoz K.K. This approval signifies an important step in expanding Biocon’s presence in the Japanese market and its commitment to global patient access to affordable medications.
Biocon Secures Japanese Marketing Approval for Pegfilgrastim Biosimilar
Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Ltd., has announced a significant milestone with the receipt of marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar. This product, a biosimilar to Neulasta®, is developed and manufactured by Biocon Biologics Ltd.
Global Market Expansion
The marketing authorization holder on behalf of Biocon is Global Regulatory Partners Japan. Sandoz K.K. has been appointed as the exclusive partner to promote, sell, and distribute the product within Japan. This strategic partnership underscores Biocon’s efforts to increase the global availability of high-quality, affordable biosimilar medications.
Strengthening Biocon’s Portfolio
This approval is a testament to Biocon’s robust pipeline and its ongoing commitment to expanding its biosimilar product offerings in key international markets. It further solidifies Biocon’s position in the Japanese pharmaceutical landscape and reinforces its mission to enhance patient access to critical therapies worldwide.
Source: BSE
